| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | -0.19 | 6e-06 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.12 | 2e-05 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-05 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-05 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.19 | 0.0002 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | -0.19 | 0.0002 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |